NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»28/09/2009 [Company watch]
KYORIN and Eisai Sign License Agreement for Development and Marketing of Uritos Tablets in China, India, Sri Lanka and ASEAN Countries

KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Co., Ltd., and Eisai Co., Ltd. announced today the conclusion of a license agreement for Uritos(R) Tablets (generic name: imidafenacin), a therapeutic agent for overactive bladder, discovered and developed by KYORIN. Under the terms of this agreement, KYORIN shall grant Eisai the exclusive rights to develop and market the agent in China, India, Sri Lanka and ASEAN countries (\"licensed territory\").

 
KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Co., Ltd., and Eisai Co., Ltd. announced today the conclusion of a license agreement for Uritos(R) Tablets (generic name: imidafenacin), a therapeutic agent for overactive bladder, discovered and developed by KYORIN. Under the terms of this agreement, KYORIN shall grant Eisai the exclusive rights to develop and market the agent in China, India, Sri Lanka and ASEAN countries (\"licensed territory\"). Overactive bladder (OAB) is a urological condition with trouble in pooling urine in the bladder. Its predominant symptom is an urge to urinate, which is often accompanied by frequent urination and nocturia, and in some cases by urge urinary incontinence. One of the major problems of OAB is the fact that patients refrain from leaving the house due to anxiety about going to the bathroom, cannot get enough sleep at night, or face limitations in their daily activities, which could lead to significantly-reduced quality of life. Anticholinergic agents that show antagonistic effects mainly on muscarinic receptor are thought to be effective in treating OAB. However, their continuous use may be limited due to the side effects such as dry mouth associated with their pharmacological effects. Uritos(R) Tablets is a new anticholinergic agent that exerts selective antagonistic effects on M3 and M1 muscarinic subtype receptors and alleviates the urge to urinate, frequent urination and urge urinary incontinence associated with OAB. The agent is highly selective for bladder, which leads to relatively low incidence of dry mouth, which is expected to contribute to improving quality of life of patients. It has been available in Japanese market since June 2007. KYORIN has been making a contribution to improving the quality of life of patients with OAB through early penetration of the agent into the Japanese market. With the conclusion of this agreement, the company will now work with Eisai to make the agent available in the licensed territory and promote the expansion of its business internationally. Eisai is making efforts to determine and meet the diversified needs of each market in the licensed territory, and will continue to actively expand and enrich its strategic product portfolio that matches the needs of the region. The conclusion of this agreement will enable KYORIN and Eisai to make further contributions to improving the quality of life and increasing benefits to patients with OAB in Asia. The companies expect the impact that the conclusion of this agreement on consolidated financial forecasts for the fiscal year ending March 31 2010 to be negligible. About Eisai Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care company that discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 8,000 people worldwide. For more information, please visit www.eisai.co.jp . About Kyorin Pharmaceutical Co., Ltd. Kyorin Pharmaceutical Co., Ltd. is in manufacturing and sales of prescription medicines and quasi-drugs, diagnostics, and industrial chemicals. Please visit www.kyorin.com.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.